Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabAlexander M. Menzies, Georgina V. Long, Shahneen Sandhu et al.|Annals of Oncology|2016Cited by 822
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyJeffrey S. Weber, Tal Zaks, Matteo S. Carlino et al.|The Lancet|2024Cited by 729
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysisJennifer L. McQuade, Michael A. Davies, Carrie R. Daniel et al.|The Lancet Oncology|2018Cited by 658
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune DisordersDouglas B. Johnson, Joseph I. Clark, Ryan J. Sullivan et al.|JAMA Oncology|2015Cited by 656
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander Eggermont, B. Guillot, Christian U. Blank et al.|The Lancet Oncology|2021Cited by 389